CO4940432A1 - (+)-norcisapride - Google Patents

(+)-norcisapride

Info

Publication number
CO4940432A1
CO4940432A1 CO98038980A CO98038980A CO4940432A1 CO 4940432 A1 CO4940432 A1 CO 4940432A1 CO 98038980 A CO98038980 A CO 98038980A CO 98038980 A CO98038980 A CO 98038980A CO 4940432 A1 CO4940432 A1 CO 4940432A1
Authority
CO
Colombia
Prior art keywords
norcisapride
fraction
solvolizing
methoxybenzoylamino
dextrorotatory
Prior art date
Application number
CO98038980A
Other languages
English (en)
Spanish (es)
Inventor
Jozef Jan Pieter Heykants
Antonius Adrianus Hendr Megens
Willem Emiel Gusta Meuldermans
Joannes Adrianus Jac Schuurkes
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO4940432A1 publication Critical patent/CO4940432A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparing Plates And Mask In Photomechanical Process (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO98038980A 1997-07-11 1998-07-09 (+)-norcisapride CO4940432A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97202161 1997-07-11
EP98200661 1998-03-04

Publications (1)

Publication Number Publication Date
CO4940432A1 true CO4940432A1 (es) 2000-07-24

Family

ID=26146686

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98038980A CO4940432A1 (es) 1997-07-11 1998-07-09 (+)-norcisapride

Country Status (30)

Country Link
US (2) US20030060485A1 (cs)
EP (1) EP1000029B1 (cs)
JP (1) JP3529102B2 (cs)
KR (1) KR100358374B1 (cs)
CN (1) CN1196681C (cs)
AT (1) ATE251139T1 (cs)
AU (1) AU757077B2 (cs)
BG (1) BG64824B1 (cs)
BR (1) BR9811676A (cs)
CA (1) CA2292480A1 (cs)
CO (1) CO4940432A1 (cs)
CZ (1) CZ296212B6 (cs)
DE (1) DE69818678T2 (cs)
DK (1) DK1000029T3 (cs)
EA (1) EA002362B1 (cs)
EE (1) EE04491B1 (cs)
ES (1) ES2209190T3 (cs)
HR (1) HRP20000004A2 (cs)
HU (1) HUP0003078A3 (cs)
ID (1) ID24228A (cs)
IL (1) IL133225A (cs)
MY (1) MY129130A (cs)
NO (1) NO315183B1 (cs)
NZ (1) NZ502207A (cs)
PL (1) PL190296B1 (cs)
PT (1) PT1000029E (cs)
SK (1) SK284941B6 (cs)
TR (1) TR200000020T2 (cs)
TW (1) TW553934B (cs)
WO (1) WO1999002496A1 (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147093A (en) 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
EP1468685A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
EP1464333A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
CA2334369A1 (en) 1998-06-15 1999-12-23 Sepracor Inc. Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
SK19052000A3 (sk) * 1998-06-15 2001-06-11 Sepracor, Inc. Použitie (+)norcisapridu alebo jeho farmaceuticky prijateľnej soli, v podstate bez jeho (-)stereoizoméru na liečenie apnoe, bulímie a iných porúch
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US7182958B1 (en) * 1999-08-03 2007-02-27 Lilly Icos Llc. β-carboline pharmaceutical compositions
US6552046B2 (en) * 2000-06-07 2003-04-22 Aryx Therapeutics Materials and methods for the treatment of gastroesophageal reflux disease
EP1347779A2 (en) * 2000-11-24 2003-10-01 Janssen Pharmaceutica N.V. Use of a triple combination comprising a 5ht3 antagonist, a 5ht4 agonist and a laxative for promoting intestinal lavage
CA2463168A1 (en) * 2001-10-08 2003-04-17 Sun Pharmaceutical Industries Limited An antispasmodic agent spaced drug delivery system
JP2003342186A (ja) * 2002-05-24 2003-12-03 Taisho Pharmaceut Co Ltd 鼻炎用内服液剤組成物
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
RU2374244C2 (ru) 2004-01-07 2009-11-27 Арикс Терапьютикс Стереоизомерные соединения и способы лечения желудочно-кишечных расстройств и расстройств центральной нервной системы
US8138204B2 (en) 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US20060247180A1 (en) * 2005-04-29 2006-11-02 Bergey James L Purgative composition and uses thereof
BRPI0615691A8 (pt) 2005-08-31 2017-08-15 Aryx Therapeutics Inc Método para a preparação de 6-((3s,4r)-4-(4-amino-5-cloro-2-metoxibenzamido)-3-metoxipiperidin-1-il) hexanoato de (r)-quinuclidin-3-ila ou sal do mesmo
KR20100026641A (ko) * 2008-09-01 2010-03-10 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
KR102718538B1 (ko) * 2017-07-19 2024-10-21 이그니타, 인코포레이티드 엔트렉티닙을 포함하는 약학적 조성물
JP2021530494A (ja) * 2018-07-11 2021-11-11 デューク・ユニヴァーシティ 胃腸障害の治療における徐放性5−ヒドロキシトリプトファンの使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4820715A (en) * 1984-06-28 1989-04-11 Bristol-Myers Company Anti-emetic quinuclidinyl benzamides
NZ225152A (en) * 1987-07-17 1990-04-26 Janssen Pharmaceutica Nv Heterocyclically substituted piperidinyl benzamides as pharmaceuticals
US4975439A (en) * 1987-09-25 1990-12-04 Janssen Pharmaceutical N.V. Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
IL89848A (en) * 1988-04-07 1997-08-14 Sepracor Chiral ester derivatives
TW213460B (cs) * 1991-02-15 1993-09-21 Hokuriku Pharmaceutical
TW294595B (cs) * 1992-11-20 1997-01-01 Janssen Pharmaceutica Nv
FR2717174B1 (fr) * 1994-03-14 1996-05-31 Sanofi Sa Utilisation de pipéridinoéthyl esters de l'acide 4-amino-5-chloro-2-méthoxybenzoïque comme 5-HT4 agonistes.
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease

Also Published As

Publication number Publication date
IL133225A0 (en) 2001-03-19
AU757077B2 (en) 2003-01-30
US20040176414A1 (en) 2004-09-09
HK1025092A1 (en) 2000-11-03
CZ296212B6 (cs) 2006-02-15
EA200000057A1 (ru) 2000-08-28
BG103934A (en) 2000-11-30
DE69818678T2 (de) 2004-07-15
TW553934B (en) 2003-09-21
IL133225A (en) 2005-12-18
WO1999002496A1 (en) 1999-01-21
DK1000029T3 (da) 2004-02-23
ID24228A (id) 2000-07-13
AU8857598A (en) 1999-02-08
PL337648A1 (en) 2000-08-28
EA002362B1 (ru) 2002-04-25
EP1000029B1 (en) 2003-10-01
KR20010014027A (ko) 2001-02-26
HUP0003078A2 (hu) 2001-01-29
NO315183B1 (no) 2003-07-28
JP2000515560A (ja) 2000-11-21
DE69818678D1 (de) 2003-11-06
CZ461799A3 (cs) 2000-05-17
ATE251139T1 (de) 2003-10-15
NO20000093D0 (no) 2000-01-07
PT1000029E (pt) 2004-02-27
ES2209190T3 (es) 2004-06-16
PL190296B1 (pl) 2005-11-30
BR9811676A (pt) 2000-09-19
CN1262675A (zh) 2000-08-09
US20030060485A1 (en) 2003-03-27
TR200000020T2 (tr) 2000-09-21
EP1000029A1 (en) 2000-05-17
CA2292480A1 (en) 1999-01-21
KR100358374B1 (ko) 2002-10-25
HUP0003078A3 (en) 2002-02-28
SK182999A3 (en) 2000-08-14
NO20000093L (no) 2000-03-10
HRP20000004A2 (en) 2000-12-31
NZ502207A (en) 2001-08-31
BG64824B1 (bg) 2006-05-31
MY129130A (en) 2007-03-30
CN1196681C (zh) 2005-04-13
SK284941B6 (sk) 2006-02-02
EE200000014A (et) 2000-10-16
JP3529102B2 (ja) 2004-05-24
EE04491B1 (et) 2005-06-15

Similar Documents

Publication Publication Date Title
CO4940432A1 (es) (+)-norcisapride
DK1001036T3 (da) Enzymatiske fremgangsmåder til spaltning af enantiomerblandinger af forbindelser, der er nyttige som mellemprodukter ved fremstillingen af taxaner
BR0013597A (pt) Compostos e métodos moduladores de receptor de androgênio
DK1054860T3 (da) Proces for syntesen af 1,3-dioler
MX9302214A (es) Derivados de taxol y proceso para su preparacion
CY1109153T1 (el) Ενωσεις υποκατεστημενου κυκλοπεντανιου και κυκλοπεντενιου χρησιμες ως αναστολεις νευραμινιδασης
CY1106486T1 (el) Μεθοδος παρασκευης 2-(κινοξαλιν-5-υλσουλφονυλαμινο) βενζαμιδικων ενωσεων
ES2158284T3 (es) Metil-fenil-oxazolidinonas quirales.
BR1100379A (pt) Composto, uso de um composto, preparação farmacêutica e processo para preparação de um composto
BR9815026B1 (pt) processo para preparar um composto, e, composto.
DK1032571T3 (da) Cykliske peridinylaminomethyl-triflourmethyl-ether-forbindelser som substans P-antagonister
BR9711311B1 (pt) derivado de 1,2,3,4-tetrahidroquinolina, composiÇço farmaceutica, uso de um derivado de 1,2,3,4-tetrahidroquinolina, e, processo para a preparaÇço de compostos.
NO20016151L (no) Fremstilling av substituerte piperidin-4-oner
DK0970939T3 (da) Fremgangsmåde til fremstilling af methanol
DE59903314D1 (de) Perfluor-n-alkansulfonsäure-derivate
ES2179529T3 (es) Compuestos biaromaticos unidos por un radical heteroetinileno, y composiciones farmaceuticas y cosmeticas que los contienen.
PA8519801A1 (es) Nuevo procedimiento para la preparacion de pirazolopirimidinonas
DK1037613T3 (da) Fremgangsmåde til fremstilling af farmaceutiske formuleringer, der indeholder en ekstrakt
IT1293777B1 (it) Processo per la preparazione di tetraazamacrocicli
DE69911603D1 (de) Synthese von 5- oder 8-bromoisoquinolin derivaten
AR037046A1 (es) Un procedimiento para la preparacion de tetralona racemica opticamente pura o enriquecida
DK0915076T3 (da) Fremgangsmåde til fremstilling af trans-(R,R)-actinol
BR9909627A (pt) Processo para a produção de r-(+)-6-carboxiamido-3-n-metila-mino-1,2,3,4-tetrahidr ocarbazol
AR021616A1 (es) Cicloheptenos sustituidos, procedimiento para su preparacion y uso de los mismos.
PT882045E (pt) Processo para a preparacao de granisetron